Video

Nab-Paclitaxel in Metastatic Breast Cancer

For High-Definition, Click

The phase III CALGB 40502 compared nab-paclitaxel at 150-mg/m2, ixabepilone, and weekly paclitaxel as treatments for patients with chemotherapy-naive metastatic breast cancer. At a second interim analysis, weekly paclitaxel and nab-paclitaxel were found to be equivalent. The findings from this study could be related to the non-standard 150-mg/m2 dose of nab-paclitaxel that was used, notes Hope S. Rugo, MD. In many cases, less is not more, Rugo states.

Nab-paclitaxel is a useful drug for patients with diabetes. Additionally, the drug does not need to be administered with steroids and has a shorter infusion time, notes Sara Hurvitz, MD. Nab-paclitaxel can also be utilized for patients who respond well to paclitaxel and remain fit for further chemotherapy, Hurvitz adds.

Switching to nab-paclitaxel can alleviate the side effects associated with allergic reactions in patients treated with frontline docetaxel or paclitaxel, suggests Rugo. Additionally, switching to nab-paclitaxel could resolve other side effects, like interstitial pneumonitis, suggests Rugo.

Fatigue can be an issue with nab-paclitaxel; however, this can be resolved using dose reductions, notes Dialecti Voudouris, MD. Another benefit of nab-paclitaxel is its ability to elicit a response in patients who have already been treated with other taxanes, notes Voudouris.

Related Videos
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
David Rimm, MD, PhD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.